Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma. After receiving FDA approval on July 14^th to begin Phase I trials, they plan to be in the clinic with their first patient the end of 2020.